Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study.
Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study.
复制标题
DOI：
10.1371/journal.pone.0147195
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Bourdette D
中科院分区：
文献类型：
--
作者：
Shinto L;Marracci G;Mohr DC;Bumgarner L;Murchison C;Senders A;Bourdette D
多发性硬化症是青年至中年成人中枢神经系统中最常见的慢性致残性疾病。抑郁症在多发性硬化症（MS）中很常见，影响50-60%的患者。在单相抑郁症的初步研究报告，当omega-3脂肪酸与抗抑郁药一起使用时，抑郁症会有所改善。本研究的目的是调查是否omega-3脂肪酸补充剂，作为一种增强疗法，改善MS患者的难治性重度抑郁症（MDD）。我们进行了一项随机，双盲，安慰剂对照的试点研究，omega-3脂肪酸每天6克，为期三个月。主要结局是蒙哥马利-艾斯伯格抑郁评定量表（MADRS）改善50%或以上。39名参与者被随机分组，31名完成了3个月的干预。在3个月终点时，两组之间MADRS的改善没有显著差异，omega-3脂肪酸组有47.4%，安慰剂组有45.5%显示出50%或以上的改善（p = 0.30）。在这项初步试验中，Omega-3脂肪酸作为MS难治性抑郁症的强化治疗与安慰剂没有显著差异。在3个月内，给予剂量的Omega-3脂肪酸补充剂耐受良好。ClinicalTrials.gov NCT00122954
Multiple sclerosis is the most common chronic disabling disease in the central nervous system in young to middle aged adults. Depression is common in multiple sclerosis (MS) affecting between 50–60% of patients. Pilot studies in unipolar depression report an improvement in depression when omega-3 fatty acids are given with antidepressants. The objective of this study was to investigate whether omega-3 fatty acid supplementation, as an augmentation therapy, improves treatment-resistant major depressive disorder (MDD) in people with MS. We performed a randomized, double-blind, placebo-controlled pilot study of omega-3 fatty acids at six grams per day over three months. The primary outcome was a 50% or greater improvement on the Montgomery-Asberg Depression Rating Scale (MADRS). Thirty-nine participants were randomized and thirty-one completed the 3-month intervention. Improvement on MADRS between groups was not significantly different at the 3-month end point with 47.4% in the omega-3 fatty acid group and 45.5% in the placebo group showing 50% or greater improvement (p = 0.30). Omega-3 fatty acids as an augmentation therapy for treatment-resistant depression in MS was not significantly different than placebo in this pilot trial. Omega-3 fatty acid supplementation at the dose given was well-tolerated over 3 months. ClinicalTrials.gov NCT00122954